

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|--|---|
| (51) International Patent Classification ⁵ : C07K 7/00, 15/28, C12N 5/20 C12N 5/12, A61K 39/395 C07H 15/00 | AI | (11) International Publication Number: WO 91/11456 (43) International Publication Date: 8 August 1991 (08.08.91) |
| (21) International Application Number: PCT/US91/00491 (22) International Filing Date: 23 January 1991 (23.01.91) (30) Priority data: 468,766 23 January 1990 (23.01.90) US 515,604 27 April 1990 (27.04.90) US 630,077 19 December 1990 (19.12.90) US (71) Applicant: TANOX BIOSYSTEMS, INC. [US/US]; 10301 Stella Link Rd., Houston, TX 77025 (US). (72) Inventor: CHANG, Tse, Wen ; 3323 Robinwood, Houston, TX 77005 (US). (74) Agent: MIRABEL, Eric, P.; Tanox Biosystems, 10301 Stella Link, Houston, TX 77025 (US). | (81) Designated States: AT (European patent), AU, BB, BE (European patent), BG, BR, CA, CH (European patent), DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, MW, NL (European patent), NO, RO, SD, SE (European patent), SU. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> | |
| (54) Title: EXTRACELLULAR SEGMENTS OF HUMAN ϵ IMMUNOGLOBULIN ANCHORING PEPTIDES AND ANTIBODIES SPECIFIC THEREFOR | | |
| (57) Abstract <p>Antigenic epitopes associated with the extracellular segment of the domain which anchors immunoglobulins to the B cell membrane are disclosed. For IgE, the epitopes are present on IgE-bearing B cells but not basophils or the secreted, soluble form of IgE. The epitope can be exploited for therapy and diagnosis. For example, antibodies or immunotoxins specific for the epitopes associated with the anchor domain of IgE can be used to selectively destroy or down-regulate IgE-bearing lymphocytes, thus blocking IgE-mediated allergic reactions. Three different isoforms of the C-terminal segment of the human ϵ chain resulting from alternative mRNA splicings in the membrane exon region are disclosed, one of which is secreted and not membrane-bound.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | ES | Spain | MG | Madagascar |
| AU | Australia | FI | Finland | ML | Mali |
| BB | Barbados | FR | France | MN | Mongolia |
| BE | Belgium | GA | Gabon | MR | Mauritania |
| BF | Burkina Faso | GB | United Kingdom | MW | Malawi |
| BG | Bulgaria | GN | Guinea | NL | Netherlands |
| BJ | Benin | GR | Greece | NO | Norway |
| BR | Brazil | HU | Hungary | PL | Poland |
| CA | Canada | IT | Italy | RO | Romania |
| CF | Central African Republic | JP | Japan | SD | Sudan |
| CG | Congo | KP | Democratic People's Republic of Korea | SE | Sweden |
| CH | Switzerland | KR | Republic of Korea | SN | Senegal |
| CI | Côte d'Ivoire | LI | Liechtenstein | SU | Soviet Union |
| CM | Cameroon | LK | Sri Lanka | TD | Chad |
| CS | Czechoslovakia | LU | Luxembourg | TC | Togo |
| DE | Germany | MC | Monaco | US | United States of America |
| DK | Denmark | | | | |

5 **EXTRACELLULAR SEGMENTS OF HUMAN ϵ IMMUNOGLOBULIN
ANCHORING PEPTIDES AND ANTIBODIES SPECIFIC
THEREFOR**

Background of the Invention

The immediate-type hypersensitivities, such as extrinsic asthma, hay
10 fever, and allergic responses to certain foods or drugs, are mediated
primarily by one isotype of the immunoglobulins, i.e., IgE. In an IgE-
mediated allergic response, the allergen binds to the IgE which is bound to
receptors on the surface of mast cells and basophilic leukocytes (basophils).
The binding of the allergen causes crosslinking of the surface IgE molecules.
15 and hence the underlying receptors for the Fc portion of IgE (Fc ϵ R),
thereby triggering the release of pharmacologic mediators such as histamine,
the slow-reacting substance of anaphylaxis (SRA), and serotonin. The
release of these mast cell and basophil products causes the pathological
reactions and symptoms of allergy.

20 IgE is secreted by a particular class of B cells, which also express IgE
on their surface. In individuals sensitized to specific allergens, the allergen-
specific IgE is continuously produced by these B cells. Nevertheless,
individuals who have no secreted IgE in their systems (and no IgE producing
B cells) appear to live normally, indicating that IgE is not essential in the
25 immune response. IgE may, however, be useful in fighting infection by
parasites.

It seems, therefore, that reducing secreted IgE by suppressing or depleting IgE producing B cells would be a viable therapy for allergy. Monoclonal antibodies (and derivative and related products) which bind specifically to the IgE producing B cells could be used in such a suppression or elimination process. The immune system's regulatory, cytolytic or cytotoxic mechanisms can be used to suppress or destroy cells which are bound by monoclonal antibodies, or by the derivative or related products.

IgE binds to the FcεR receptors on the surface of basophils and mast cells very strongly, with an association constant, K_a , of about 1×10^{10} liter/mole. Even though IgE is not synthesized by basophils and mast cells, the very strong and stable association of IgE with FcεR means that IgE is virtually always present and exposed on the surface of these cells. Thus, an immunotherapeutic agent targeting the IgE on B cells must not react with the IgE on basophils and mast cells, in order to avoid cross-linking this IgE and the underlying FcεR and thereby triggering an allergic reaction.

Summary of the Invention

Immunoglobulins consist of two peptide chains, a heavy chain and a light chain. In IgE, the heavy chain is designated as the ε chain. Membrane anchoring peptides extend from the C terminus of the heavy chains of the immunoglobulins and affix the associated immunoglobulin to the cell membrane surface. These membrane anchoring peptides can be divided into

three segments in terms of locations in relation to the plasma membrane. The middle segments have 25 hydrophobic and uncharged amino acid residues, suggesting that they are in the membrane lipid bilayer. The C-terminal hydrophilic segments have 3-28 amino acid residues, suggesting that they are intracellular. The segments toward the N-termini contain about 13 to 67 amino acid residues, and are highly acidic and hydrophilic, suggesting that they are on the extracellular surface of the plasma membrane.

The extracellular segments of these peptides are unique for different isotypes. Therefore, the extracellular segment of the ϵ chain membrane anchoring peptide forms, in whole or in part, an epitope unique to the B cells which produce IgE. However, this membrane-bound immunoglobulin isotype specific ("*migis*") extracellular epitope is not present on secreted, soluble IgE (or on IgE bound to the Fc ϵ R) because only the IgE which is bound to the surface of B cells contains the membrane anchoring peptide as part of its heavy chain. The antibodies and other immunotherapeutic agents of the invention bind to the *migis* epitopes on the surface of IgE-bearing B cells. These B cells can then be eliminated or controlled by a number of immune mechanisms. These antibodies and other immunotherapeutic agents can be used in *in vivo* or extracorporeal allergy therapy, and in diagnosis, as described further below.

One advantage in therapy of these antibodies and related

immunotherapeutic agents over those that bind epitopes common to IgE in both bound and secreted form, is that the latter will form an immune complex of antibody-IgE. The immune complex may create problems with kidney or other physiological functions.

5 It has been discovered that because of alternative mRNA splicings, there are at least three different nucleotide sequences which encode for peptides in the membrane anchoring region of human ϵ chain. The deduced amino acid sequences encoded by these three nucleotide sequences are also different, indicating that there are three different isoforms of the human ϵ
10 chain membrane anchoring peptide.

The deduced amino acid sequence of isoform I shows that it has 67 amino acid residues, and a 15 amino acid peptide segment toward the N-terminus. This 15 amino acid segment is proposed to be extracellular and to form, entirely or in-part, the *migis* epitope. Isoform II has 119 amino acid
15 residues, 67 of which are towards the N terminus and form the proposed extracellular segment. Isoform III, having 45 amino acid residues, is secreted and does not have a membrane-bound extracellular segment.

Brief Description of the Drawings

Fig. 1 shows three different mRNA splicings which create three
20 different proposed isoforms of human ϵ membrane anchoring peptide (I, II, and III). "*" indicates a stop codon in the reading frame. The short solid-black segment at the end of the CH4 domain represents the C-terminus of

the secreted ϵ chain.

Fig. 2A shows the peptide-coding nucleotide sequence and the deduced amino acid sequence of isoform I of the membrane anchoring peptide of human ϵ chain. The underlined segment is the hydrophobic amino acid stretch thought to span the membrane lipid bilayer; the bold-faced segment is the portion presumably exposed to the exterior cell surface.

Fig. 2B shows the peptide-coding nucleotide sequence and the deduced amino acid sequence of isoform II of the membrane anchoring peptide of human ϵ chain. The bold-faced segment indicates amino acid sequences unique to isoform II.

Fig. 2C shows the peptide-coding nucleotide sequence and the deduced amino acid sequence of isoform III, which is in the membrane anchoring region of human ϵ chain. The bold-faced segment indicates amino acid sequences unique to isoform III.

Figs. 3A and 3B respectively show the locations of the DNA probes which can be used for screening the cDNA library for clones containing the human ϵ chain membrane anchoring peptides, for secreted and membrane-bound IgE.

Fig. 4 shows the binding of HEM7 to various *migis* peptides. Results are the means of duplicates from one representative of three ELISAs, using microtiter plates coated with polyclonal human serum IgE (\diamond) or synthetic *migis* peptides, \bullet *migis*- ϵ ; \square , *migis*- μ ; \circ , *migis*- γ ; Δ , *migis*- α ; ∇ , *migis*- δ .

Fig. 5C shows binding of HEM7 to IgE-secreting cells as determined by fluorescence flow cytometry. Fig. 5B shows binding of TES-19, a mAb to secreted IgE (positive control), with binding at equivalent concentrations (10 μ g/ml) to SKO-007 cells. Fig. 5A is control without antibody added.

5 Fig. 6A shows the concentration-dependent binding of HEM7 to IgE-secreting SKO-007 cells at various concentrations.

Fig. 6B shows the specific inhibition of HEM7 binding to SKO-007 cells by *migis- ϵ* peptide. ● HEM7 and *migis- ϵ* peptide; ○, HEM7 and *migis- γ* peptide; ▲, TES-19 and *migis- ϵ* peptide. Values shown represent the
10 means of three separate determinations.

Fig. 7 Western immunoblotting analysis of membrane-bound IgE with HEM7. The relative migration of the M.W. markers is shown on the left, and the positions of membrane bound ϵ and secreted ϵ on the right.
a, serum IgE probed by polyclonal anti- ϵ ; b, serum IgE probed by HEM7;
15 c, plasma membranes of SKO-007 cells probed by polyclonal anti- ϵ ; d, plasma membranes of SKO-007 cells probed by HEM7; e, plasma membranes of SKO-007 cells probed by HEM7 in the presence of *migis- ϵ* peptide at 100 μ g/ml.

20 Detailed Description of the Preferred Embodiments and Their Manner and Process of Making and Using

1. *Migis* Epitopes and Their Uses in Therapy and Diagnosis

Membrane-bound immunoglobulins on B cells differ from the

secretory, soluble immunoglobulins synthesized by the same B cells in that the former have an extra peptidic piece that anchors them onto the B cell surface. The membrane-bound immunoglobulins on B cells from different species, for which amino acid sequences have been determined, have extra
5 isotype-specific regions that anchor the immunoglobulins to the membrane. These peptidic regions have lengths ranging from 41 to 130 amino acids and can be divided into three segments. There is a middle segment of 25 hydrophobic and uncharged amino acids, which is believed to be located in the cytoplasmic membrane bilayer. There is a C-terminal hydrophilic
10 segment of 3-28 amino acid residues, which is believed to be located on the cytoplasmic side of the membrane. There is a segment toward the N-terminus of about 13 to 67 amino acid residues, which is highly acidic and hydrophilic and proposed to lie on the extracellular surface of the plasma membrane.

15 The length and the hydrophilic and highly charged nature of the extracellular segment indicate that this segment is exposed and accessible to antibodies. The antigenic epitopes located on the extracellular segment of the membrane-bound region of immunoglobulin heavy chains are designated herein as the *migis* epitopes. The *migis* epitopes allow for
20 developing several types of monoclonal or polyclonal antibody-based therapies and diagnoses for IgE-mediated allergic diseases.

2. Membrane Anchoring Peptides of B Cell Membrane-bound Immunoglobulins

The amino acid sequences of ten membrane-bound immunoglobulins from several species have been previously determined. See Ishida, N. et al., EMBO J., 1:1117 (1982); Steen, M. L. et al., J. Mol. Biol., 177:19-32 (1984); Rogers, J. et al., Cell, 26:19-27 (1981); Yamawaki-Kataoka, Y. et al., Proc. Natl. Acad. Sci., MSA, 79:2008-2012 (1982); Kamaromy, M. et al., Nuc. Acids Res., 11:6775-6785 (1983); Rogers, J. et al., Cell, 20:303-312 (1980); Bernstein, K. E., J. Immunol. 132:490-495 (1984); Cheng, H. et al., Nature, 296:410-415 (1982). These sequences indicate certain common features of the membrane anchoring peptides. As shown in Table 1, and as discussed above, the membrane anchoring peptide has three segments which are distinguishable based upon their locations in relation to the plasma membrane.

Table 1. Key features and properties of membrane anchoring peptides.

| Number of Amino Acid Residues | | | | |
|-------------------------------|----|----|----|----|
| Immunoglobulin 1. | 2. | 3. | 4. | |
| Class/Subclass | | | | |
| Mouse IgE2 | 19 | 25 | 28 | 72 |
| Rat IgE | 19 | 25 | 28 | 72 |
| Mouse IgG ₁ | 18 | 25 | 28 | 71 |
| Mouse IgG _{2a} | 18 | 25 | 28 | 71 |
| Mouse IgG _{2b} | 18 | 25 | 28 | 71 |
| Mouse IgG ₃ | 18 | 25 | 28 | 71 |
| Mouse IgM | 13 | 25 | 3 | 41 |
| Human IgM | 13 | 25 | 3 | 41 |

| | | | | |
|-----------|----|----|---|----|
| Human IgD | 27 | 25 | 3 | 55 |
| Mouse IgD | 26 | 25 | 3 | 54 |

1. Designates the first (N terminal) segment of the anchoring peptides, which is hydrophilic and highly acidic, and is proposed to lie on the exterior surface of the cell membrane.
2. Designates the middle segment of the anchoring peptides, which is hydrophobic with no charged residues, and is proposed to lie in the membrane lipid bilayer.
3. Designates the last (C terminal) segment of the membrane anchoring peptides, which is hydrophilic and is proposed to lie in the cell cytoplasm.
4. Represents the total number of amino acid residues in each different membrane anchoring peptide shown.

The shortest *migis* peptides have 13 amino acid residues (mouse and human μ chains). See Table 1. The *migis* peptides of all immunoglobulins contain high proportions of charged amino acid residues, almost entirely acidic residues, as shown in Table 2. The proportions of charged amino acid residues and polar hydrophilic residues account for very high percentages of the amino acid composition of the *migis* peptides (Table 3). Thus, it is proposed that all the *migis* peptides are exposed and long enough to be accessible by antibodies.

Table 2.

The amino acid sequences of *migis* peptides.

| | 26 | 21 | 16 | 11 | 6 | 1 |
|-------------------------|-------|-------|-------|-------|-------|----|
| Mouse IgE | ELDIQ | DLCIE | EVEGE | ELEE | | |
| Rat IgE | ELDIQ | DLCIE | EVEGE | ELEE | | |
| Mouse IgG ₁ | GLQLD | ETCAE | AQDGE | LDG | | |
| Mouse IgG _{2a} | GLDLD | DVCAE | AQDGE | LDG | | |
| Mouse IgG _{2b} | GLDLD | DICAE | AKDGE | LDG | | |
| Mouse IgG ₃ | ELELN | GTCAE | AQDGE | LDG | | |
| Mouse IgM | EGEVN | AEEEG | FEN | | | |
| Human IgM | EGEVN | AEEEG | FEN | | | |
| Human IgD | YLAMT | PLIPQ | SKDEN | SDDYT | TFDDV | GS |
| Mouse IgD | IVNTI | QHSCI | MDEQS | DSYMD | LEEN | G |

Table 3. Composition of charged amino acid residues and polar, hydrophilic amino acid residues of the *migis* peptides.

| 5 | | Acidic residues | Basic residues | Polar résidues | hydrophilic residues | Proportion of hydrophilic residues % |
|-----------------------|-------------------------|--------------------|-------------------|-------------------|-------------------------|---|
| # Amino acid residues | | | | | | |
| 10 | Mouse IgE | 10 | 0 | 2 | 12 | 63 |
| | Rat IgE1 | 10 | 0 | 2 | 12 | 63 |
| | Mouse IgG ₁ | 6 | 0 | 4 | 10 | 56 |
| | Mouse IgG _{2a} | 7 | 0 | 2 | 9 | 50 |
| | Mouse IgG _{2b} | 7 | 1 | 1 | 9 | 50 |
| 15 | Mouse IgG ₃ | 6 | 0 | 4 | 10 | 56 |
| | Mouse IgM | 6 | 0 | 2 | 8 | 61 |
| | Human IgM | 6 | 0 | 1 | 7 | 54 |
| | Human IgD | 6 | 1 | 8 | 15 | 56 |
| | Mouse IgD | 7 | 0.5 | 9 | 16.5 | 63 |
| 20 | | | | | | |

Acidic residues: E (Glu), D (Asp)

Basic residues: K (Lys), R (Arg), H (His); His is partially charged.

Polar residues: S (Ser), T (Thr), C (Cys), Q (Gln), N (Asn)

25 **3. Determining the Amino Acid Sequence of the Human ϵ Chain *migis* Peptides.**

A number of well established procedures can be applied to determine the DNA sequence corresponding to the human ϵ chain *migis* peptides. One approach is to start with the mRNA preparation of a human myeloma cell line which expresses IgE on the surface. SKO-007 cells can be employed for

30 this purpose. With the mRNA preparation, one can establish a cDNA

library by employing lambda phage or plasmids as cloning vectors. A preferred method for constructing the cDNA library is with the cDNA Library Construction System Kit - Librarian I developed and commercialized by Invitrogen (San Diego, CA). A stepwise detailed instruction manual is provided for RNA isolation from cells, reverse transcription, second strand synthesis, linker ligation, agarose gel sizing of cDNA, electroelution to purify cDNA, vector ligation, and transformation of E. coli. The vector used in this library is pCDM8.

In the screening of the cDNA library for clones containing the *migr* peptides, several probes can be used. As shown in Fig. 3A, the library can be screened with DNA probe A, which is a 1.1 kb long U266 cDNA covering most of length of ϵ mRNA (no membrane-bound segment). The positive clones, which include both secreted and membrane-bound forms can be distinguished by using additional probes. Probe B is developed by taking advantage of the probable fact that the end of the CH4 domain is truncated in the human ϵ chain membrane anchoring peptide. The truncation occurs when the gene segments of the CH4 domain and the membrane-bound domain are translocated. The loss of the C-termini also occurs with the membrane bound forms of other immunoglobulins, including ϵ and μ , which contain CH4 domains. From the published information on the nucleotide sequence of human ϵ .CH4 domain, the most possible splicing donor site is intracodon GT, 71 bp 5' of the termination codon TGA. Another GT, which

is not intracodon and less likely a splicing donor site, is closer to the terminus (24 bp 5' to the termination codon).

The specific location for probe B is indicated in Fig. 3A. Probe B will react with the secreted form of the ϵ chain gene and not the membrane-bound form of ϵ chain gene.

The design of probe C (Fig. 3B) was based on the finding that the transmembrane segment of the membrane anchoring peptides is very conserved among all the immunoglobulin genes so far sequenced. There is a segment of peptide and corresponding coding DNA within this transmembrane segment that is nearly identical among all immunoglobulins. As shown in Table 4, the consensus DNA sequence with the eight combinations was used as probe C.

Table 4. A conserved region in the transmembrane peptide segment of the membrane anchoring peptides.

| | | 1 | 2 | 3 | 4 | 5 |
|----|------------------------------|-----|-----|-----|-----|-----|
| | | Leu | Phe | Leu | Leu | Ser |
| 5 | Mouse IgE | CTG | TTC | CTG | CTC | AG |
| | Rat IgE | CTG | TTC | CTG | CTC | AG |
| | Mouse IgG ₁ | CTC | TTC | CTG | CTC | AG |
| | Mouse IgG _{2a} | CTC | TTC | CTG | CTC | AG |
| | Mouse IgG _{2b} | CTC | TTC | CTG | CTC | AG |
| 10 | Mouse IgG ₃ | CTC | TTC | CTC | CTG | AG |
| | Mouse IgM | CTG | TTC | CTG | CTG | AG |
| | Human IgM | CTG | TTC | CTG | CTG | AG |
| | Human IgD* | CTC | TTC | ATC | CTC | AC |
| | Mouse IgD* | CTC | TTC | CTG | CTC | AC |
| 15 | Consensus sequence (Probe C) | CT | TTC | CT | CT | AG |
| | | C | | C | C | |
| | | G | | G | G | |

*Human and mouse IgD's have Thr (ACX) in the 5th amino acid residue; human IgD also has Ile (ATC) in the 3rd amino acid residue. These are the variations not covered by the consensus sequence.

Probe D which represents a segment upstream of the most probable splicing donor site, GT, consists of 36 bp. This probe should react with ϵ chain gene of both the secreted and membrane-bound forms.

Table 5 summarizes the pattern of reactivities of clones containing ϵ genes of secreted or membrane-bound forms with the four probes.

Table 5. The reactivity of ϵ gene-containing cDNA clones with probes A, B, C, and D.

| | <u>ϵ Secreted</u> | <u>ϵ Membrane-bound</u> |
|---------|---------------------------------------|---|
| 30 | | |
| Probe A | + | + |
| Probe B | + | - |
| Probe C | - | + |
| Probe D | + | + |

The library size needed to clone the membrane-bound ϵ chain depends on how abundant the mRNA is. Assuming secreted IgE comprises 0.1% of the SKO-007 poly A⁺ RNA, the library size should be about 5,000 independent recombinant clones to have a 99% probability to isolate a positive clone. In IgE-producing rat immunocytoma IR2 and IR162 cells, mRNA for the membrane-bound form of ϵ chain was found to be more than 2% of that of the secreted form. Assuming this ratio of membrane-bound/secreted forms of ϵ chain holds true for the human IgE-producing SKO-007 cells, the cDNA library size needed to isolate the membrane-bound ϵ chain is about 250,000. In a preferred procedure, a larger number of clones (about 1,000,000) are screened.

An alternative to the conventional approach of establishing a cDNA library and screening the clones representing the cellular mRNA species is to amplify the mRNA to produce high proportions of their corresponding DNA. The resulting DNA can then be purified by gel electrophoresis and then subjected to sequence analysis. The methodology, referred to as polymerase chain reaction (PCR) amplification, has been established in the past few years and complete systems including reagents and equipment have been commercialized. One preferred system is provided by Perkin Elmer Cetus (Norwalk, CT), and includes the GeneAmp DNA Amplification Reagent Kit and the DNA Thermal Cycler.

Some of the specific reagents used in this approach are the same as used

for the cDNA library cloning. Since no sequence of the ϵ chain membrane anchoring peptide has been determined, the strategy is to amplify both the secreted and membrane-bound forms of ϵ chains. Two primers are to be used, one is oligo.dT (25-30-mers) and one is the oligomer corresponding to probe D in Figure 3. Probe D is located 5' to the most probable splicing donor site and therefore primes both the secreted and membrane-bound forms of ϵ mRNA and DNA. After sufficient amplification, the two populations of DNA fragments are resolved by gel electrophoresis. The secreted form of the ϵ chain can be distinguished by its reactivity with probe

10 B. The purified DNA's are then subjected to DNA sequencing.

PCR amplification seems to be a more efficient procedure than cDNA cloning, because mRNA encoding the *migis- ϵ* peptide is poorly represented in the poly A⁺ RNA pool. The U266 ϵ chain cDNA (U266 being the parent cell line of SKO-007 with the same mRNA and cDNA) can be used to work out some preliminary annealing conditions between template DNA and

15 oligo-primers.

Another approach for obtaining a DNA clone containing genes encoding the membrane-bound segments is to screen the human genomic DNA library. A preferred source for this human genomic library is constructed using human lung fibroblast WI38 cells provided by Stratagene (La Jolla,

20 CA). The genes are in lambda vector and the inserted DNAs have average sizes of 15K bp. Identification of the clones can be achieved by hybridiza-

tion with U266 ϵ chain cDNA. The location of the gene segment corresponding to the membrane anchoring peptide can be determined by using a probe prepared from the homologous mouse gene of the transmembrane segment (probe C of Figure 3 and Table 4). The sequence of the gene segment encoding the membrane anchoring peptide is then
5 determined.

3A. The Nucleotide Sequence of DNA Encoding the Membrane Anchoring Peptide of Human ϵ Chain

The nucleotide sequence of genomic DNA encompassing the encoding
10 segments for the membrane anchoring peptide of human membrane bound ϵ chain was determined by screening the human genomic library as described above. The sequences of Isoforms I, II and III are shown respectively in Figs. 2A, 2B and 2C, along with the deduced amino acid sequences for portions of the membrane anchoring peptide. The assignment
15 of the exons was made by identifying the nucleotides for splicing donors and acceptors (as shown in Fig. 1) and by comparison to the published homologous sequences of mouse membrane-bound ϵ chain and of immunoglobulins of other classes.

For isoform I, the *migris* peptide is identified as the first fifteen amino
20 acids encoded by membrane exon I, as indicated by the bold-faced amino acids in Fig. 2A. This precedes a stretch of about 25 hydrophobic amino acids (underlined in Fig. 2A) which form the transmembrane region. Two

possible structures of *migis* peptides (Isoform I) are shown below.

Structure I

SH
Glu·Leu·Asp·Val·Cys·Val·Glu·Glu·Ala·Glu·Gly·Glu·Ala·Pro·Trp

Structure II

S
Glu·Leu·Asp·Val·Cys·Val·Glu·Glu·Ala·Glu·Gly·Glu·Ala·Pro·Trp

S
Glu·Leu·Asp·Val·Cys·Val·Glu·Glu·Ala·Glu·Gly·Glu·Ala·Pro·Trp

- 10 3B. The Nucleotide Sequence of DNA Encoding Various Isoforms of Membrane Anchoring Peptide of Human ϵ Chain

International Application No. PCT/US88/04706 describes how to determine the nucleotide and amino acid sequences of the antigenic epitopes located on the extracellular segment of the membrane-bound region of the human ϵ chain. These epitopes are designated as the $\epsilon_{mb/ec}$ epitopes. Several approaches are possible, including starting with a mRNA preparation of a human myeloma cell line which expresses IgE on the surface. The mRNA can be used in establishing a cDNA library which is then screened with DNA probes for the transmembrane region gene segment of ϵ chain region.

An alternative approach, also described in International Application No. PCT/US88/04706, is to use PCR technology to successively amplify and purify the DNA sequence of the ϵ transmembrane region. The DNA is then

sequenced.

Another alternative approach described in International Application No. PCT/US88/04706 is to screen the human genomic library. The gene segment corresponding to the membrane bound region can be determined
5 with a probe prepared from the homologous mouse gene of the transmembrane segment, and the sequence of this segment is then determined.

In the present invention, the initial nucleotide sequencing was performed on the cDNA derived from mRNA isolated from human cells
10 expressing membrane-bound IgE. A commercially available human IgE expressing myeloma, SKO-007 (from the American Type Culture Collection ("ATCC") Rockville Maryland), was used.

The DNA segments of cDNA regarded as pertinent to identification and characterization of the transmembrane regions of human ϵ chain were
15 amplified by PCR, as described further below.

A. Construction of a Transfectoma Expressing Chimeric IgE.

Before proceeding to sequencing of the ϵ chain genome, a cell line secreting a hu/mu chimeric IgE and expressing membrane-bound IgE was generated to use in determining the reactivities of monoclonal antibodies
20 with membrane-bound IgE on B cells. For constructing the chimeric ϵ and κ genes, the constant regions of human ϵ and κ genomic DNA and the variable regions of genomic DNAs of the heavy and light chains of a

monoclonal antibody, BAT123 (specific for gp120 of HTLV-III_B strain of HIV-1), were used. The variable region genes of BAT123 had been isolated from the functional heavy and light chain loci and used in the construction of murine/human ($\gamma 1/\kappa$) fusion genes for the production of chimeric BAT123 (hu $\gamma 1/\kappa$). See International Patent Application No. PCT/US88/01797. By replacing the human γ constant region with the ϵ constant region in the heavy chain expression vector, a chimeric BAT123 (hu ϵ, κ) with an antigen binding region derived from BAT123, was produced in a similar approach.

10 A λ phage clone containing the human germ line ϵ constant region was identified with a probe representing a segment of the constant domains (CH1-4) of ϵ chain. From this phage, a 6.4-kb DNA segment containing domains CH1 to CH4 and a 2.5 kb 3'-flanking sequence was subcloned into pUC19. By analogy to the reported mouse and rat ϵ -loci information, the
15 presumed membrane exons were estimated to be located within the 1 Kb SacI fragment at the 3'-end of the ϵ gene. The 1 Kb SacI fragment was subcloned and sequenced to establish the presence of any membrane exon-like sequences.

The 6.4 kb DNA segment containing ϵ domains CH1 to CH4 and the
20 membrane exons was linked to the BAT123 V_H gene to give the chimeric mouse/human ϵ gene. This chimeric ϵ gene, together with the chimeric κ gene, were co-transfected into Sp2/0 cells by electroporation. The

transfected cells were selected by the gpt and neo gene activities in the presence of mycophenolic acid and G418. The procedure was similar to that described in International Patent Application No. PCT/US88/01797.

Stable transformants were established and analyzed for IgE secretion
5 by ELISA, and for membrane IgE expression (by fluorescence flow cytometry). A clone, SE-44 was chosen for further studies. The cumulative IgE concentration in the culture supernatant of the SE-44 cells at 10^6 /ml was established to be 40 μ g/ml.

To test for Ig expression on the cell surface by fluorescence flow
10 cytometry, cells were incubated with anti-human IgE antibody, and developed with fluorescein labeled goat (Fab')₂ anti-mouse IgG. Cells Sp2/0, SKO-007, and chimeric IgE expressing cells were then fixed in 1% paraformaldehyde and analyzed on a Coulter EPICS flow cytometer. Fluorescence profiles for Sp2/0, SKO-007, and chimeric IgE expressing cells,
15 respectively, were also run in the absence of primary staining antibody. Cell surface staining by anti-human IgE was estimated to be 60% and 50% for SE-44 and SKO-007 cells, respectively.

To further confirm that SE-44 cells express both membrane exons 1 and 2, the 1 kb SacI segment was separated into three portions utilizing the
20 restriction enzyme ApaI. The two 250 bp fragments containing membrane exon 1 and its 5'-flanking region were used as the probe specific for exon 1. The 400 bp fragment containing exon 2 and the 3'-untranslated region was

used as the exon 2 probe. These probes were used separately in Northern analyses to hybridize with cytoplasmic RNAs. Both probes yielded similar results and lit up messages of 3,000 and 3,600 nucleotides in length for SE-44 and SKO-007, respectively. The observation that SE-44 cells expressed shorter membrane-IgE messages than SKO-007 cells was expected. Since there is no termination/polyadenylation (t/pA) signals within the 1 kb SacI fragment, the chimeric ϵ gene used the SV40-derived t/pA signal present in the gpi gene construct for expression. The SKO-007 membrane IgE messages probably represent the normal intact transcripts using the endogenous ϵ -locus t/pA signal which is located 600 bp (estimation based on the size difference of the two messages) downstream from the 3'-end of the 1 kb SacI fragment. Northern analysis therefore suggests that both exons 1 and 2 are transcribed in these cells.

An identical Northern blot was also hybridized with the ϵ (CH1-4 domains) probe. Transcripts of approximately 2,300 nucleotides in length were noted for both SE-44 and SKO-007, in addition to weak bands characteristic for membrane IgE-specific messages.

Binding inhibition assays were used to demonstrate that the chimeric BAT123 (human ϵ, κ) bound to gp120 with an affinity constant comparable to that of BAT123 or chimeric BAT123 (hu $\gamma 1, \kappa$). In experiments examining the binding of BAT123-HRP conjugate to solid phase gp120 in competition with BAT123 itself, chimeric BAT123 (hu $\gamma 1, \kappa$), and chimeric

BAT123 (hu ϵ 1, κ) the replacement of mouse C γ 1 in BAT123 with human C γ 1 or human ϵ did not affect its antigen-binding affinity significantly.

B. Cloning and nucleotide sequencing of cDNA segments encoding the transmembrane region of human ϵ immunoglobulin.

5 In addition to SE-44, the cell line SKO-007, which also expresses human ϵ chain on its cell surface and which is a subclone of U266, was obtained from the ATCC. U266 was a myeloma cell line established from a blood sample of a myeloma patient.

10 Total RNA was extracted in guanidinium thiocyanate from 5×10^7 SKO-007 or SE-44 cells. The first strand cDNA was synthesized by AMV reverse transcriptase (Life Sciences, Inc., Petersburg, FL) according to the procedure described by the manufacturer.

The mRNA was reverse-transcribed using the oligo-dT primer into cDNA, which was then used as the template in PCR to amplify the pertinent
15 segments covering the 3' end of the CH4 exon and the membrane exons. Several oligonucleotide primers, with the following sequences, were used in the PCR:

- #1: 5'-GAGGAATTCCTGGTGCAGTGGCT-3'
#2: 5'-GGGAATTCCTGGTGGAGCGTGAGTGGCC-3'
20 (complementary strand was used)
#3: 5'-CAGAATTCAGATGAGTTCATCTGCCGTGC-3'
#4: 5'-GCGAATTCGATGCAGAGGCCGGTCCACG-3'
(complementary strand was used)
#5: 5'-AGGGACTGCCGAGAGCAGCA-3'
25 #6: 5'-CTCGGCAGTCCCTGCTGCTGT-3' (complementary strand was used)
(The underlined sequence is the introduced *Eco*RI site for use in other studies.)

The major products derived from PCR were either subjected to direct sequencing or cloned into a Bluescript II vector. The nucleotide sequences were determined for several clones derived from each individual band. The electrophoretic patterns of the PCR products and the sequencing data indicated unexpectedly the existence in both SKO-007 and SE44 cells of RNA species other than the one derived from the splicing of CH4 domain to the previously predicted *me.1* and *me.2* exons. When primers #1 and #2 were used, the dominant PCR product was a segment originating from the direct RNA splicing of CH4 domain to *me.2*, using the predicted donor and acceptor sites, leaving out the *me.1* domain (Fig. 1). When these first-round PCR products were used as the template for a second round PCR using primers #3 and #4, two major products were observed (Figs. 2A and 2B): one originated from the splicing of CH4 domain to *me.1* using the predicted donor and acceptor sites and the other was from the splicing of CH4 to a previously unidentified acceptor site 156 bp 5' of *me.1* (the segment between this acceptor site and *me.1* is referred to as *me.p*). However, when primers #3 and #4 were used on cDNA as the template (first round PCR), the dominant product was a segment resulting from the splicing of CH4 domain to *me.p* (Fig. 2C).

Additional PCR experiments using other pairs of primers also substantiate the observation of splicing from CH4 to *me.p*. When primers #3 and #6 were used, the major product revealed the splicing of CH4

domain to *me.p*, resulting in the generation of combined *me.p* and *me.1* segments (called *me.1'* domain). When primers #5 and #2 were used, the splicing of the earlier predicted donor site at the 3' end of *me.1* and the acceptor site at the 5' end of *me.2* was established. So far, no other splicing combination has been found. Thus, these analyses revealed at least three forms of mRNA's of ϵ chain derived from the alternative splicings in the gene segment encoding the membrane peptide: isoform I contains CH4-*me.1-me.2*; isoform II contains CH4-*me.1'(me.p+me.1)-me.2*; isoform III contains CH4-*me.2'*.

10 C. Analysis of ϵ mRNAs by Northern blotting methods

Experiments were also carried out to identify the specific mRNA species in the RNA preparations from SKO-007 and SE44 cells by mRNA/DNA hybridization methods. 32 P-labeled probes with sequences complementary to mRNA encoded in *me.p*, *me.1*, and *me.2* segments were prepared by PCR and employed in Northern hybridization analyses for examining the presence of RNA species containing the represented segments. All these three probes were shown to hybridize with the mRNA from both cell lines on the Nylon membrane. The ϵ mRNA species detected in SE44 cells were all smaller than the corresponding species in SKO-007 cells.

20 Because isoform III is substantially smaller than isoform I or II and was resolved from isoform I and/or II in the electrophoretic gel, the *me.2* probe revealed two bands, one with and one without *me.1'* (or *me.1*) exon.

On the other hand, because the *me.1* probe could hybridize with both isoforms I and II, which were not resolvable in the gel, the Northern blotting analysis did not establish the presence of isoform I mRNA. In summary, the analyses with *me.p* and *me.2* probes suggest convincingly the presence of mRNA's of isoforms II and III. In addition, the intensity of bands also suggest that the amounts of mRNA's of these isoforms and their relative proportions are different in SKO-007 and SE44 cells. The results with *me.p* and *me.1* probes indicate the SKO-007 cells have more isoforms I/II (combined) than SE44 cells. The results with *me.2* probe suggest that SKO-007 cells have comparable amounts of isoforms I/II and isoform III, while SE44 cells have more isoform III than isoforms I/II.

D. Predicted amino acid sequences corresponding to *me.p* and *me.2'* segments

Based on the nucleotide sequences of the PCR-amplified segments, the corresponding amino acid sequences for isoforms II and III were deduced and compared to that of isoform I. The reading frame of isoform II is the same as isoform I. The extra 52 a.a. (bold-faced in Fig. 2B) lengthens the extracellular segment of the membrane-anchor peptide to a total of 67 a.a. from 15 a.a. in isoform I (Fig. 2A). The omission of the *me.1* (length 122 bp, not a multiple of 3) causes the reading frame of *me.2'* segment in isoform III to be shifted (Fig. 2C); the peptide coding sequence is lengthened from 81 bp (encoding 27 a.a.) to 134 bp (encoding 45 a.a.).

The corresponding peptide of isoform III (Fig. 2C) does not contain

the hydrophobic stretch of 25 a.a. thought to span the membrane lipid bilayer (the segment is encoded by *me.I*). This suggests that it is secreted, and is not membrane-bound.

4. Developing Antibodies to the *migis* Peptides

5 Peptides containing any of isoforms I, II or III, or segments or immunologic equivalents of these peptides, can be used as immunogens. Polymers based on the immunogenic peptides can also be used, where the immunogenic peptide amino acid sequences, or equivalent sequences, are the polymer repeat unit. Immunogenic peptides based on isoform I may be
10 in either the monomeric or dimeric form shown above. Immunogenic peptides based on isoform II may be in either the monomeric or dimeric form.

Such immunogenic peptides (designated herein as the peptides of the invention) can be synthesized by conventional techniques, such as with the
15 RaMPS system (DuPont DeNemours & Co.), which applies Fmoc chemistry. Alternatively, recombinant peptides or immunoglobulin heavy chains (or portions thereof) containing isoforms I, II, or III may be biosynthesized by expressing in *E. coli* or eukaryotic cells the gene segments containing the coding sequence of these peptides.

20 When using a synthetic peptide segment as an immunogen, it is usually more effective to conjugate it to a protein carrier, for example, hepatitis B surface antigen, core antigen, or preferably keyhole limpet hemocyanin.

(KLH). If the peptidic segment lacks a lysine residue or if the lysine residue is in the middle part of the segment, it is desirable to add a lysine residue at the C-terminal end. Because the N-terminus already has an α -amino group, the modified synthetic peptidic will have two available amino groups for linking.

Multiple molecules of peptides can be conjugated to each molecule of the carrier protein. With KLH, a preferred molar ratio for peptide/KLH is 10. The method of conjugation is very well established. Cross-linkers such as glutaraldehyde or bis (sulfosuccinimidyl) suberate or preferably disulfosuccinimidyl tartrate (Catalogue #21579, 20591, Pierce Chemical Co., Rockford, IL) can be used.

As immunogens, these peptides can be used to make monoclonal antibodies which are specific for them, using the protocol described further below. Specific examples of making monoclonal antibodies to the *migis* epitope of human ϵ chain appear below and in priority U.S. Patent Application Serial Nos. 07/531,787, filed June 1, 1990, and 07/468,766, filed on January 23, 1990.

The immunogenic peptides of the invention can also be used to immunize rabbits, goats, rats, or mice (or even another human being) to prepare polyclonal antibodies to the extracellular *migis*- ϵ epitopes. Monoclonal antibodies that react with the peptides of the invention can be further screened for positive specific reactivity with cells bearing a specific

isotype. The monoclonal antibodies can then be applied in vivo. Polyclonal antibodies made against peptides of the invention, however, generally contain almost entirely antibodies that react with the synthetic peptide but not the native molecules. Whether the polyclonal antibodies made against synthetic peptides can react with intact cells must be tested.

When preparing monoclonal antibodies, it is not necessary to use the synthetic or recombinant peptides in both immunization and antibody identification. For example, in immunizing mice for preparing spleen cells for fusion with myeloma cells, the immunogen may be the membrane-bound immunoglobulin isolated from the plasma membrane of immunoglobulin-bearing myeloma cells, such as the IgG-expressing IM-9 cell line, or it may be the myeloma cells themselves. Transfectomas, which are developed by transfecting mouse myeloma cells with genes of human immunoglobulin heavy chains and light chains and which express on their cell surface membrane-bound immunoglobulins, may also be used as immunogens.

Lymphocytes from the spleen or lymph nodes of immune mice and rats can also be used to prepare hybridomas secreting monoclonal antibodies specific for the extracellular *migis-ε* epitopes. A preferred fusion protocol is to fuse immune spleen cells of mice with non-secreting mouse myeloma cells, such as NS-1 or Sp2/0 cells, using polyethylene glycol.

A preferred immunization protocol for preparing monoclonal antibodies is to inject into each mouse 50 μg of the conjugate of KLH and

the recombinant or synthetic peptides of the invention in complete Freund's adjuvant. Two and four weeks later, the same amount of antigen is given subcutaneously in incomplete Freund's adjuvant. After about six weeks, the fourth antigen injection is given intraperitoneally in saline. Mice are sacrificed 4 days after the last injection and the spleens are removed for preparing single cell suspensions for fusion with myeloma cells.

A similar protocol can be used for immunization with purified native human membrane-bound immunoglobulins (having attached membrane anchoring peptide segments) isolated from the plasma membrane of immunoglobulin-bearing human myeloma cells, such as IM-9 cells. When human immunoglobulin-bearing cells are used as the immunogen, 1×10^7 cells are injected intraperitoneally at two week intervals.

The fusion procedure with polyethylene glycol and other various procedures concerning cloning and hybridoma culturing have been well established. The preferred fusion procedure is the well-known one described by Hudson, L. and Hay, F.C. (Practical Immunology, 2nd edition, pp. 303-313, 1980, Blackwell Publishing Co., Boston).

The screening of hybridomas for monoclonal antibodies (or the identification of polyclonal antibodies) reactive with the extracellular *migis-e* epitopes can be performed with an enzyme-linked immunosorbent assay (ELISA) using the synthetic peptide as the solid phase antigen. A preferred solid phase antigen is the conjugate of a peptide of the invention with a

carrier protein different from that used in the immunogen, such as bovine serum albumin or ovalbumin. Monoclonal antibodies specific for a particular peptide of the invention (corresponding to one of the isoforms) can then be screened for specific binding to B cell lines and B cells expressing that isoform by using immunofluorescence flow cytometric analyses.

Generally, the *migis-ε* epitope-specific monoclonal antibodies which are first obtained will be murine-derived, and thus may be immunogenic or allergenic in human therapy. It is therefore desirable to produce chimeric antibodies (having an animal variable region and a human constant region), or to use human expression vectors (Stratagene Corp., La Jolla, California) to produce fragments of human antibodies (V_H , V_L , F_v , F_d , Fab , or $F(ab')_2$) and then construct whole human antibodies using techniques similar to those for producing chimeric antibodies. In addition, one can create antibodies in which the entire constant portion and most of the variable region are human-derived, and only the antigen binding site is derived from some other mammal. See Riechmann, L. *et al.*, Nature 332:323-327 (1988). Further, one can create single peptide chain antibodies in which the heavy and light chain F_v regions are connected. See Huston, J.S. *et al.*, Proc. Natl. Acad. Sci. USA 85:5879-5883 (1983). All of the wholly and partially human antibodies are less immunogenic than mammalian equivalents, and the fragments and single chain antibodies are less immunogenic than whole antibodies. All

these types of antibodies are therefore less likely to evoke an immune or allergic response. It is noted that an immune response could deplete the antibodies which are administered before such antibodies could function to suppress the immune response.

5 Monoclonal antibodies specific for the *migis-ε* epitopes can be used to reduce or eliminate the B cells expressing IgE by antibody-dependent cellular cytotoxicity (ADCC), complement-mediated cytotoxicity, or other cytolytic or regulatory immune mechanisms. For example, antibodies of certain IgG subclasses, such as mouse IgG_{2a} and human IgG₁ and IgG₃, can
10 mediate ADCC carried out by certain Fc receptor-bearing phagocytic leukocytes. Administration of such mouse IgG_{2a} antibodies, chimeric antibodies bearing human γ-1 or γ-3 chains, or human IgG₁ or IgG₃ antibodies can be used to down-regulate or lyse B cells expressing IgE. These antibodies will not bind to the secreted form of IgE or to IgE bound
15 to the surface of basophils or mast cells.

The mAbs of the invention can also be used as targeting agents for cytotoxic cells.

The mAbs of the invention can also be used as carrier agents of cytotoxic drugs or for delivering an effector substance, by conjugating the
20 mAbs to these substances. A toxin-antibody conjugate will bind and directly kill B cells producing IgE, but not B cells producing other isotypes. These toxins are cytolytic or cytotoxic agents, including cytotoxic steroids, gelonin,

abrin, ricin, Pseudomonas toxin, diphtheria toxin, pokeweed antiviral peptide, tricarhecum, radioactive nuclides, and membrane-lytic enzymes (such as phospholipase).

5 The antibody and the agent can be conjugated by chemical or by genetic engineering techniques. The toxin-antibody conjugates may be used alone or in combination with the free antibodies of the invention.

The antibodies of the invention (and the toxin conjugates, fragments, and other derivatives) are administered systemically, and preferably intravenously. They can be administered in any pharmaceutically acceptable
10 vehicle.

Another therapeutic alternative involves active immunization, wherein antibodies specific to the *migis-ε* epitopes are endogenously produced in vivo. These endogenously produced antibodies bind the *migis-ε* epitopes and cause destruction of the associated B cells. Production of such antibodies
15 can be induced either by administering an immunogenic *migis* peptide of the invention, or a paratope-specific, anti-idiotypic antibody. Anti-idiotypic antibodies against the paratope of the antibodies of the invention bear the internal image of the *migis-ε* epitopes. These anti-idiotypic antibodies can be used to actively immunize against the *migis-ε* epitopes and induce the
20 endogenous formation of antibodies against the *migis-ε* epitopes. Such paratope-specific, anti-idiotypic antibodies are administered to a patient in an immunogenic amount sufficient to induce the formation of antibodies

against B cells expressing IgE. These anti-idiotypic antibodies are preferably administered as chimeric antibodies or human antibodies, to minimize any immune response against them. They may also be any of the antibody fragments, V_H , V_L , F_v , F_d , Fab , or $F(ab')_2$ (which also may be chimeric or human in nature).

Certain factors, such as granulocyte monocyte-colony stimulating factor (GM-CSF) or monocyte-colony stimulating factor (M-CSF), are known to induce the proliferation of leukocytes, including those mediating ADCC. In in vitro experiments, GM-CSF and M-CSF have been shown to augment the ADCC activity on tumor cells mediated by monoclonal antibodies specific for surface antigens expressed on the tumor cells. The therapeutic effect of specific monoclonal antibodies of the invention, conjugates, or polyclonal antibodies in depleting IgE-expressing B cells could perhaps be enhanced by combining them with factors that augment ADCC activities.

Derivative antibodies can be made which draw cytotoxic cells such as macrophages or cytotoxic T cells toward the targeted immunoglobulin-expressing B cells. These derivative antibodies include bi-specific antibodies having a specificity for a receptor of a cytotoxic cell and a specificity for the targeted IgE-expressing B cells. Such hybrid bi-specific antibodies can include two different Fab moieties, one Fab moiety having antigen specificity for the targeted *migis-ε* epitopes, and the other Fab moiety having antigen specificity for a surface antigen of a cytotoxic cell, such as CD3 or CD8.

The bi-specific antibodies of the invention can be a single antibody having two specificities, or a heteroaggregate of two or more antibodies or antibody fragments. See, e.g., C. Reading, U.S. Patent Nos. 4,474,893 and 4,714,681; Segal *et al.* U.S. Patent No. 4,676,980.

5 While monoclonal antibodies of the invention can be used for *in vivo* applications, they may also be used in extra-corporeal *ex-vivo* applications. The IgE-bearing B cells in the circulation of the patients can be removed by an affinity matrix (antibody immobilized on a solid phase) which is conjugated with the monoclonal antibodies of the invention.

10 Another use for the antibodies of the invention is for determining numbers and relative proportions of B lymphocytes bearing particular isotypes in mixed leukocyte populations. The *migis-ε* specific antibodies will not react with cells which bear secreted immunoglobulins via such cells' Fc receptors. Such cells include macrophage and activated T cells. The profile
15 of the B cells may indicate the allergic status of the individual, and whether further depletion of IgE-bearing B cells is desirable. The same information can also indicate how much antibody is needed to deplete a substantial portion of B cells bearing IgE. For this purpose, antibodies can be used in standard assays which are used to determine cell surface antigens. In
20 general, the antibodies are contacted with a sample of the leukocytes to be tested under conditions which allow the antibodies to bind IgE-bearing cells in the sample. The cells are then examined for binding of antibody. This

can be accomplished by conventional cell staining procedures, for example, a fluorescently labeled second antibody can be used to detect binding of antibody.

The monoclonals (or polyclonals) can also be further characterized. An immunofluorescence assay could be used to determine whether the antibodies of the invention bind to basophils. An immunofluorescence assay could also be used to determine whether the antibodies bind to mast cells, and to determine whether the antibodies of the invention react with SKO-007 myeloma cells, IgE-bearing B cells, and transfectomas expressing human/murine chimeric IgE. The results for the HEM7 mAb to isoform I are shown below in Fig. 6. An ELISA is used to determine reactivity with synthetic *migis-ε* peptides and with soluble IgE.

Table 6. The Reactivity of Antibodies Specific for *migis-ε* Peptide with Different IgE-Containing Targets.

| | Reactivity | Assays |
|----------------------------------|------------|-----------------------------|
| Synthetic <i>migis-ε</i> peptide | + | ELISA |
| Soluble IgE | - | ELISA |
| SKO-007 myeloma cells | + | Immunofluorescence staining |

5. Experiments with Animal Models.

The substances and methods of the invention are likely to be tested on animal model systems. Two of the most relevant systems are the following.

A. Asthma/Rhesus Monkey Model

The monoclonal antibodies specific for human *migis* peptides and their

related substances of this invention (some of which are described further below) are intended for use to treat patients with various IgE-mediated allergies (see section 6 below). Among these allergies, extrinsic asthma is a more serious form. An experimental model system for studying asthma
5 has been established in rhesus monkeys.

A small portion of rhesus monkeys, which have been infected with the nematode Ascaris suum, develops sensitivity to extract of ascaris. When these sensitive monkeys are given spray containing ascaris antigen, they develop breathing problems resembling asthma. Patterson, R., J. Clin. Invest. 57:586-593 (1976).
10

The various substances of this invention can be tested in the asthma/rhesus monkey model system. The ascaris sensitive monkeys are given the experimental treatment or control treatment and measurements are made to determine:

- 15
- (a) Do the asthma symptoms upon ascaris challenge decline?
 - (b) Does the circulating IgE decline?
 - (c) Do the circulating IgE-bearing B cells decline?
 - (d) Does the IgE density on basophils decline?

B. Mouse model system

20 Mice are not known to develop allergic symptoms naturally. However, for demonstrating the pharmacologic mechanisms of the intended therapy by depleting IgE-bearing B cells and IgE, the mouse can serve as an excellent

model.

The extracellular mouse ϵ chain *migis* peptide has already been sequenced. Ishida, N. *et al.* EMBO J. 1:1117-1123 (1982) The 19 amino acid residue peptide is:

5 Glu·Leu·Asp·Leu·Gln·Asp·Leu·Cys·Ile·Glu·Glu·Val·Glu·Gly·Glu
 Glu·Leu·Glu·Glu

This peptide is synthesized in several forms, including one that has extra Leu-Lys residues at the C-terminus.

10 The peptide and its KLH conjugate are used as antigens to immunize rabbits and goats. The antisera are collected. The antigen-specific antibodies are purified using a column of Sepharose 4B conjugated with the peptide (with Leu-Lys addition) or with peptide linked to bovine serum albumin. Normal mice are injected intravenously (i.v.) or intraperitoneally (i.p.) with the purified antibodies (or their related substances), with the
15 peptide (with Leu-Lys addition), or with peptide linked to bovine serum albumin. The mice are preferably immunized with the mouse *migis*- ϵ peptide conjugated to a carrier protein, such as keyhole limpet hemocyanin. After the treatments, the mice may also be challenged by infection with a parasite, Nippostrongylus brasiliensis, which is known to induce large
20 quantities of IgE. Snapper, C.M. *et al.* Immunol. Rev. 102:51-75 (1988).

The questions to be addressed include the following:

- (a) Does the total IgE in circulation decline?

- (b) Does the number of IgE-bearing B cells decline?
- (c) Does the density of IgE on the surface of basophils decline?
- (d) Do IgM and IgG specific for the mouse *migis-ε* peptide cause different effects? The purpose of this test is to determine the effect of ADCC on the depletion of IgE-bearing B cells. IgG, but not IgM, is known to mediate ADCC.

5

6. Therapy of IgE-Mediated Allergy Based upon the Selective Elimination of IgE-Producing Cells.

10 Antibodies specific for the *migis-ε* epitopes bind IgE on the surface of IgE-producing B cells and not on basophils and mast cells. This differential binding of IgE-bearing cell types provides the basis for therapeutic uses of the antibodies.

Conventional anti-IgE antibody will bind IgE on the surface of mast cells and basophils and trigger the release of pharmacological mediators of allergy. To be effective in therapy, the antibodies of this invention cannot bind IgE on these cells.

15 The antibodies specific for *migis-ε* epitopes can be used to treat IgE-mediated allergies in humans or other animals (e.g. dogs, cats and horses). The antibodies can be used therapeutically in several ways, including as effector agents mediating an immune function, as carrier agents of toxins or cytotoxic drugs, for delivering an effector substance, or as

20

targeting agents for cytotoxic cells.

A. Antibodies specific for IgE-producing cells.

Antibodies of certain IgG subclasses, such as mouse IgG2a and human IgG1 and IgG3, can be used to reduce or eliminate the IgE-bearing B cells by ADCC, complement-mediated cytotoxicity, or other cytolytic or regulatory immune mechanisms. These antibodies can also be used as effector agents mediating an immune function or as targeting agents for cytotoxic cells. The antibodies can be systemically administered, preferably intravenously, as free antibodies to patients afflicted with IgE-mediated allergy in amounts sufficient to eliminate substantially IgE-producing cells and consequently, to substantially eliminate IgE.

The antibodies can also be administered nasally. On the lining of the nasal channels and the respiratory tract are areas in which active mast cells are concentrated. The IgE-producing B cells and free IgE in the extravascular space of these tissues may have better access to the basophils and mast cells than IgE-producing B cells and IgE in other parts of the body. Nasal administration (e.g., by nasal spray) may be used to deliver relatively high concentrations of therapeutic antibodies into these areas and thus to achieve speedier and more effective results. The antibodies can also be administered ocularly.

The mAbs of the invention may be used therapeutically in humans, and related mAbs against corresponding *migis* epitopes may be used

therapeutically in other mammals, such as dogs, cats and horses. For therapeutic uses in humans, the human or humanized antibodies (and fragments) including chimeric antibodies, are preferred. Human and humanized antibodies are less immunogenic in humans than non-human antibodies. Consequently, they are better suited for *in vivo* administration, especially when repeated or long term administration is necessary.

Immunotherapies employing the antibodies of this invention may be used in combination with conventional desensitization immunotherapy. For example, desensitization with allergen may be performed in conjunction with the administration of either anti-*migis-ε* antibodies or antibody-toxin conjugates discussed above to substantially eliminate IgE producing cells.

Desensitization induces IgG production against the allergen/immunogen. Inducing such IgG production may be most effective as an allergy therapy when IgE-producing B cells are substantially depleted. The combination of antibody and desensitization therapy is attractive because although the IgE-producing B cells may only be temporarily depleted (for a few weeks or months) by the anti-*migis* antibody, and will eventually re-populate, the desensitization effect may last much longer.

20 B. Immunotherapy Combining an *migis-ε*-Specific Antibody and a Factor Enhancing ADCC.

The therapeutic effect of *migis-ε* epitope-specific monoclonal antibodies, polyclonal antibodies or antibody-immunotoxin conjugates in treating

allergies should be enhanced by combining antibody therapy with factors that augment ADCC activities, such as GM-CSF (granulocyte monocyte-colony stimulation factor) or M-CSF (monocyte-colony stimulation factor).

C. Immunotoxins Specific for IgE-Producing Cells.

- 5 Antibodies specific for a *migis-ε* epitope can be combined with one or more of the immunotoxins noted above, thereby forming an antibody-immunotoxin conjugate which specifically targets IgE-producing B cells. The immunotoxins may be used alone or in combination with free anti-*migis* antibodies.

10 D. Extracorporeal Treatment

- While the *migis-ε*-specific monoclonal antibodies can be used for *in vivo* therapy they may also be used in extra-corporeal *ex-vivo* therapy. The IgE in the circulation of allergic patients can be removed by an affinity matrix (antibody immobilized on a solid phase) that is conjugated with the
15 monoclonal antibodies of this invention. Because antibodies may leak out from the affinity column and enter into the circulation of the patient, the monoclonal antibodies of the invention are preferable to other antibodies that can induce histamine release from basophils and mast cells.

7. Diagnostic Uses

- 20 Another use for the antibodies of the invention is for determining numbers and relative proportions of IgE-bearing B lymphocytes in mixed leukocyte populations. The *migis* specific antibodies will not react with cells

which bear secreted immunoglobulins via such cells' Fc receptors. Such cells include macrophages and activated T cells. The profile of the B cells may indicate the immune status of the individual. The same information can also indicate how much antibody is needed to deplete a substantial portion of B cells bearing a particular isotype, where some of those B cells are tumorous. For this purpose, antibodies can be used in standard assays which are used to determine cell surface antigens. In general, the antibodies are contacted with a sample of the leukocytes to be tested under conditions which allow the antibodies to bind isotype-bearing cells in the sample. The cells are then examined for binding of antibody. This can be accomplished by conventional cell staining procedures, for example, a fluorescently labeled second antibody can be used to detect binding of antibody.

The invention is illustrated further by the following examples.

Example L CONFIRMING MONOCLONAL ANTIBODY REACTIVITY
WITH *MIGIS-ε* EPITOPES

Two different mAbs to the *migis-ε* epitopes were prepared. The preparation procedures are described below.

A. Preparing Monoclonal Antibody E46-13-3

Monoclonal antibodies against an epitope unique to membrane-bound IgE but not secreted IgE (isoform I) were prepared by a standard procedure for preparing hybridomas, as described in the Detailed Description of the Invention. The immunogen for immunizing BALB/c mice was the above-

described SE-44 transfectoma cells. The mice were injected intraperitoneally 3 times at 2 weeks intervals with 1×10^7 SE-44 cells that were treated with 1mM mitomycin C for 30 minutes at 37°C prior to injection.

For initial screening of fusion wells, the human *migis-ε* peptide
 5 Glu·Leu·Asp·Val·Cys·Val·Glu·Glu·Ala·Glu·Gly·Glu·Ala·Pro·Trp
 dimerized, was used as coating antigen for ELISA. The positive clones were characterized in additional assays with other peptides and SE-44 cells and control cell lines.

From the several thousand fusion wells resulting from two fusion
 10 experiments, one hybridoma clone E46-13-3 was found to have specificity for the *migis-ε* peptide (Table 7).

TABLE 7.
 Specific Binding of Monoclonal Antibody E46-13-3 to Human *migis-ε*
 Peptide in ELISA.

| | | |
|----|--------------------------------------|------------------|
| 15 | <u>Solid-phase antigen (2 μg/ml)</u> | A ₄₅₀ |
| | <i>migis-ε</i> peptide - ovalbumin | 2.707 |
| | HIV-1 peptide* - ovalbumin | 0.011 |
| | <i>migis-ε</i> peptide - KLH | 2.773 |
| | HIV-1 peptide - KLH | 0.002 |
| 20 | KLH | 0.005 |

*The HIV-1 peptide was a 15-mer peptide representing a segment of gp120 of HTLV-III_B strain of HIV-1. This peptide is reactive with BAT123 monoclonal antibody.

E46-13-3 and other monoclonal antibodies were further analyzed for

reactivities with SE-44 cells compared to various control cell lines, including Sp2/0, the parent cell line for the transfectoma SE-44. Included in the control was the IM-9 cell line, which expresses IgG and CD23 on the cell surface, and the DAKIKI cell line, which expresses IgA on its surface. The tests were carried out with flow cytometric analyses with FITC-goat-anti-mouse IgG using an EPICS system. The results (shown below in Table 8) show clearly that E46-13-3 stained SE-44 specifically.

Table 8. Live cell staining studies of E46-13-3.

| Cells | E46-13-3 | Net percent positive cells | |
|-------------------------|----------|--------------------------------|---------------------------------|
| | | Control Monoclonal antibody | Anti-IgE Monoclonal antibody |
| SE44 | 39.5 | 58.1 (anti-IgE) | 58.1 |
| Sp2/0 | 2.6 | — | 3.6 |
| IM-9 | 1.4 | 85.1 (anti-IgG) | 0 |
| IM-9 coated with IgE | 0 | 84.3 (anti-IgG) | 60.6 |
| DAKIKI | 1.1 | 82.0 (anti-IgA) | 0 |

* IM-9 is a human IgG-expressing lymphoblastoid cell line; DAKIKI is a human IgA-expressing lymphoblastoid cell line. Both were obtained from ATCC.

B. Preparing Monoclonal Antibody HEM7

The *migis* peptides of all five human immunoglobulin heavy chain isotypes (including *migis-ε*) with an additional C-terminal lysine residue were synthesized. Conjugates of these *migis* peptides with keyhole limpet hemocyanin (KLH; Sigma) or with ovalbumin (Sigma) were prepared by cross-linking 1 mg/ml each with 0.04% glutaraldehyde (Sigma) in phosphate buffered saline (PBS), pH 7.4, for 16h at 4°C, and dialyzed to PBS. Under

these conditions more than 90% of the peptide was cross-linked.

BALB/c mice were then immunized subcutaneously and intraperitoneally with 100 μ g *migis- ϵ* -KLH in Freund's adjuvant 4 times and then intraperitoneally twice with mitomycin C (Sigma)-treated (20 mg/ml for 20h) SE44 mouse myeloma cells (which express human IgE on the cell surface). Spleen cells were fused with Sp 2/0 cells using polyethylene glycol (Carbowax, Fisher). Supernatants of growing hybrids were screened in enzyme-linked immunosorbent assay (ELISA) for reactivity to *migis- ϵ* ovalbumin. Positive wells were then tested for ability to bind to cell surface IgE by indirect immunofluorescence flow cytometric analyses.

The HEM7 hybridoma secreted an antibody showing specificity in these assays and was subcloned by limiting dilution. Antibodies from culture supernatants were purified by protein A (Repligen)-affinity chromatography.

The purified mAb HEM7 was analyzed for specific binding to the *migis- ϵ* peptide and to mIgE. The *migis* peptides of the four other heavy chain isotypes (IgG, IgA, IgM, and IgD) were also synthesized and the reactivity of HEM7 with these peptides was examined. These *migis* peptides are at least 13 a.a. long and apparently hydrophilic, containing 6 or 7 acidic amino acids. The *migis* peptides show a great degree of heterogeneity; although *migis- μ* and *migis- γ* are the most homologous to *migis- ϵ* .

In the ELISA microtiter plates (Immulon 2; Dynatech) were coated at 1 μ g/ml PBS with *migis- ϵ* peptide, and the *migis- μ* , *migis- γ* , *migis- α* , *migis- δ*

peptides, as well as with *migis-ε* peptide-ovalbumin conjugate, or with human serum IgE (Ventrex), or other serum proteins (Jackson Immunoresearch), for 16h at 22°C. Plates were post-coated with blocking buffer, containing 5% non-fat dry milk (Carnation), 0.05% Tween 20 (Sigma) in PBS for 1h at 22°C. Binding of murine antibodies (1h, 22°C) was detected using peroxidase-conjugated goat anti-mouse IgG (Kirkegaard and Perry) and a tetramethyl benzidine (TMB) substrate solution containing 10 µg/ml TMB (Sigma) and 0.0036% H₂O₂, acidified with 0.7 M H₂SO₄, and absorption at 450nm was quantitated using an ELISA plate reader (Bio-Tek).

10 HEM7 was shown to bind to *migis-ε* peptide reaching maximal binding at 100 ng/ml antibody concentration. It did not bind to any measurable extent to the *migis* peptides of the other four isotypes (Fig. 4). Furthermore, HEM7 even at 10 µg/ml did not bind to soluble, secreted IgE purified from human serum (Fig. 4). Nor did it bind to IgE purified from supernatants of SE44 cells, or to other human Igs or serum substances (data not shown).

15 The purified HEM7 mAb was also tested for its ability to bind to IgE-bearing SKO-007 cells in immunofluorescence flow cytometric assays.

The immunofluorescence flow cytometric assays were carried out as follows. Cultures of B cells secreting various human immunoglobulins and other human blood cell lines were obtained from the ATCC. Peripheral 20 blood was obtained by venipuncture from adult volunteers and mononuclear cells were isolated using Ficoll-Paque (Pharmacia). Cultured cells were

stained with antibodies and fluorescence quantitated by flow cytometry (EPICS-V, Coulter Diagnostics). Peripheral blood lymphocytes and monocytes were gated by their light scattering properties. Presence of surface markers was confirmed using mAb reagents specific for
5 IgE(HP6029), IgG(HP 6046), IgM(HP6081), IgD(JA11), and IgA(2D7) (all from Zymed), and for other leukocyte surface markers (CD4, CD14, CD45 and CD23) (from Becton-Dickinson).

Inhibition of binding of HEM7 to SKO-007 cells by *migis* peptides was also assayed. These assays were performed by preincubating the mAb
10 HEM7 or TES-19 (30 μ g/ml) with *migis* peptides for 1h on ice before cells were added to the mixture.

HEM7 was able to bind to SKO-007 cells (obtained from the ATCC) as shown in the flow cytometric profiles in Figs. 5A-5C. In this immunofluorescence staining histogram of SKO-007 cells using HEM7 mAb,
15 it can be seen that the fluorescence of the entire SKO-007 cell population shifted to higher levels, indicating that all cells are reactive with HEM7. The immunofluorescence staining is comparable to that observed with TES-19, a mAb specific for human IgE, used as a positive control.

Maximal binding of HEM7 to SKO-007 cells could be achieved at 10-30
20 μ g/ml (Fig. 6A). Furthermore, the binding of HEM7 to SKO-007 cells could be nearly completely inhibited by *migis*- ϵ peptide at 1 μ g/ml, a concentration approximately equimolar to the antibody present (Fig. 6B).

In contrast, the *migis-γ* peptide did not inhibit HEM7 binding substantially even at a 1000-fold higher concentration. Nor did the *migis-ε* peptide inhibit the binding of TES-19 mAb to SKO-007 cells.

HEM7 was also tested for its ability to bind to human cells bearing other surface Ig. Among the various human cell lines tested, HEM7 was able to bind to SKO-007 cells and to the related U266 cells that bear mIgE, but not to B cell lines expressing IgM, IgD, IgG, or IgA. The mAb also did not bind to any other cells tested, including a T cell line, a monocyte-like cell line, and peripheral blood mononuclear cells (Table 9).

TABLE 9.

Reactivity of mAb HEM7 with various human cell types*

| Cell type | Surface marker | Positive cells (%) |
|---------------------------------|----------------|--------------------|
| SKO-007 (myeloma cell line) | IgE | 46 |
| U266B1 (myeloma cell line) | IgE | 22 |
| IM-9 (B lymphoblast line) | IgG | 0 |
| RPMI 1788 (B lymphoblast line) | IgM, IgD | 2 |
| DAKIKI (B lymphoblast line) | IgA | 0 |
| CCRF-CEM (T lymphoblast line) | CD4, FcγR | 0 |
| U-937 (Monocyte-like cell line) | CD23 | 0 |
| Peripheral blood lymphocytes | CD45 | 0 |
| Peripheral blood monocytes | CD45, CD14 | 3 |

*The reactivity was quantitatively determined by indirect immunofluorescence staining employing flow cytometric methods as described above. The percents of positive cells were determined as the increase of percents of cells with fluorescence levels above a set threshold after incubation in HEM7 at 10μg/ml, in comparison to the percents of these cells when a negative control mAb was used. Values shown are from one representative of three experiments. Values of < 5% positive cells are

within the variability of the assay.

The specific binding of HEM7 to mIgE was further examined by Western immunoblotting analyses using the plasma membrane fraction isolated from disrupted SKO-007 cells. The Western immunoblotting was carried out as

5 follows.

Proteins in purified polyclonal human serum IgE (0.1 μ g, Ventrex) and a plasma membrane fraction from SKO-007 cells (25 μ g) were fractionated on 10% SDS-PAGE and electroblotted onto nitrocellulose. The filters were incubated with either peroxidase-conjugated polyclonal goat anti-human ϵ chain at 2.5 μ g/ml, or with HEM7 at 25 μ g/ml, followed by peroxidase-conjugated goat anti-mouse IgG, and TMB with membrane enhancer substrate (enzyme conjugated antibodies and substrate from Kirkegaard and Perry). M. W. markers were from BioRad.

15 Goat anti-human IgE (ϵ chain specific) revealed two bands in the area of about 80kDa (M.W.); HEM7 reacted with only the higher M.W. band (Fig. 7). These results suggest that the plasma membrane preparation was contaminated with secreted IgE, which was the lower M.W. (80kDa), denser band stained by goat anti-human ϵ and that HEM7 reacted only with the membrane-bound form of ϵ chain, which has a higher M.W. (87kDa)

20 because it contains the extra membrane-anchoring segment. Again, the immunoblotting reaction of HEM7 with the specific protein in the nitrocellulose membrane could be inhibited by the *migis- ϵ* peptide (See

column c of Fig. 7). Immunoblots of polyclonal human serum-derived IgE showed no reactivity with HEM7 (column b), nor did immunoblots of plasma membrane fractions from a control cell line (IM-9) secreting IgG.

HEM7 was also checked to determine if it would cause histamine release from peripheral human blood basophils, which cells were taken from four individuals. Each assay was run using various concentrations of TES-17 mAb (a mAb specific for human IgE which induces histamine release from leukocytes) and HEM7. Polyclonal antibodies to human IgE (which also induce histamine release) served, in addition to TES-17, as an additional positive control. Goat anti-mouse IgG was added to some of the tests as an enhancer.

It was shown that HEM7 did not cause histamine release in a mAb dose-dependent fashion, irrespective of whether the enhancer was present.

Example II. CONFIRMING THAT ISOFORM II EXISTS, *IN VIVO*, AND THAT IT IS MEMBRANE-BOUND

The predicted isoform II contains 52 additional amino acids between Cε4 and the 15 amino acid segment bound by HEM7. Monoclonal and polyclonal antibodies were prepared to 36 amino acid synthetic peptide corresponding to residues 6 to 40 of the 52 amino acid segment. Both in ELISA and on immunoblots, the antibodies react with IgE from cell lysates but not with IgE from cell culture supernatants, suggesting that isoform II exists on cells and is not secreted. Moreover, on immunoblots, the 15 amino acid band recognized by HEM7 co-migrates with that recognized by the

antibodies to the 36 amino acid segment.

Example III. CONFIRMING THE *IN VIVO* EXISTENCE OF ISOFORM III mRNA AND PEPTIDE

A. Detecting ϵ_2 mRNA in Human Lymphocytes by PCR

5 Experiments were conducted to ensure that isoform III mRNA was produced by human peripheral blood lymphocytes.

For the convenience of presentation, the predicted ϵ chain encoded by the mRNA with CH4-*me.2'* splicing (designated as isoform III above) is referred to below as ϵ_2 and the conventional ϵ chain of secreted IgE (designated as isoform I above) is referred to as ϵ_1 . IgE molecules 10 containing one or two ϵ_2 chains are referred to as IgE₂ and IgE molecules containing only ϵ chains are IgE₁.

The PBMC from an allergic patient, whose serum IgE concentration was about 1 μ g/ml (about 10-20 times average), were isolated and the total RNA 15 from these cells was prepared. After the first strand cDNA template was generated, PCR was performed using a pair of primers, one of which was located in CH4 domain and the other in the *me.2* domain. The PCR-amplified products were analyzed by gel electrophoresis and the DNA in the major bands were subcloned and their nucleotide sequences determined.

20 The major PCR product using the cDNA template derived from the RNA of SKO-007 and SE44 cells was a segment of ϵ_2 mRNA. The same segment was also the major product with the cDNA from the human PBMC preparation. An autoradiograph showed that the ³²P-labeled DNA probe

corresponding to an *me.2* segment hybridized with the ϵ_2 segment. It also hybridized with two other bands, corresponding to two segments derived from two isoforms of membrane-bound ϵ chain mRNA. Nucleotide sequencing of DNA fragments cloned from these bands confirmed this conclusion.

5 B. Detecting ϵ_2 Chains in Culture Medium of Human IgE-secreting Cell Lines

A 33 a.a. peptide corresponding to an *me.2'* segment and an additional C-terminal lysine residue, was synthesized. The peptide had the sequence:

10 SHAAGEAPDLPR LHQRPPAPRLAAGHSRSTRPS.

The peptide, designated the "E2T peptide," was conjugated to KLH and used to immunize mice, using a standard protocol described above. Monoclonal antibodies were made which bound to the E2T peptide specifically. These mAbs also bound to ϵ_2 , as determined on immunoblots.

15 The E2T peptide, conjugated to KLH, was also used to immunize rabbits. The resulting antibodies specific for E2T were affinity purified by a small column of agarose beads conjugated with E2T. This purified anti-E2T was conjugated with horseradish peroxidase and to agarose beads. These various reagents were then used in ELISA and immunoblotting assays to detect ϵ_2 chain and IgE₂. In the ELISA with anti-E2T as the solid-phase immunoadsorbent and peroxidase-labelled goat antibodies against human IgE as the tracer, ϵ_2 chain could be detected in the culture supernatant of SE44 cells, and to less extent, in that of SKO-007 cell. The substance was

20

absent in the media of SP2/0 cells and of CAG1-51-4 cells.

Since the variable regions of the heavy and the light chains and the antigen specificity of the chimeric IgE (ϵ , κ) secreted by SE44 cells and of the chimeric IgG (γ 1, κ) secreted by CAG1-51-4 cells are identical, the binding of the ϵ_2 chain or IgE₂ from the media of SE44 and SKO-007 cells to the solid phase was not due to the variable regions. The ϵ chain in the culture supernatant of SE44 cells did not bind to rabbit antibodies specific for an irrelevant antigen.

The possibility that anti-E2T could react with membrane-bound ϵ chain (designated as " ϵ_m chain") was examined by testing its binding to a recombinant ϵ_m chain. The recombinant ϵ_m , which extended from CH2 domain to the membrane anchoring peptide, was produced in *E. coli* and purified by affinity column. An ELISA showed that mAb E11-4-70, which reacts with ϵ_1 chain, and mAb HEM7, which is specific for the extracellular 15 a.a. segment of the membrane anchor peptide, reacted with the recombinant ϵ_m , while anti-E2T did not. These results indicate that the cytoplasmic segment of ϵ_m , which is encoded by the same exon as E2T but using a different reading frame, is not reactive with anti-E2T, and that the ϵ chain in the culture supernatant of SE44 cells, that was reactive with anti-E2T, was not ϵ_m possibly shed from the cellular plasma membrane.

C. Detection of IgE₂ by Western Blot Analyses and Affinity Adsorption

The IgE secreted by SE44 cells into the culture medium was affinity

purified by a mAb, TES-61, which is presumed to be specific for CH domains of IgE. The purified IgE was gel electrophoresed with or without treatment of reducing agents, transblotted onto nitrocellulose filters, and reacted with various antibodies to be studied. In the blots transferred from a nonreducing gel, both horseradish peroxidase-conjugated goat anti-human IgE and anti-E2T stained a band of about 200 Kd, indicating that ϵ_2 chain was present in IgE molecules and not as single chains. In addition, both in the reducing and nonreducing conditions, anti-E2T reacted with substances with M.W. at the higher end of those bands stained by goat anti-human IgE.

10 Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

CLAIMS

1. An antibody preparation which binds specifically to immunoglobulin bound to the membrane of B cells but not to the secreted form of the immunoglobulin.
- 5 2. An antibody preparation of Claim 1, wherein the immunoglobulin is human IgE.
3. An antibody preparation of Claim 1, which is monoclonal.
4. An antibody preparation which specifically binds to an epitope formed at least in part by the membrane anchoring peptide of an immunoglobulin.
- 10 5. An antibody preparation of Claim 4, wherein the immunoglobulin is human IgE.
6. An antibody preparation of Claim 4, wherein the epitope is located on the extracellular segment of the membrane-bound domain of an immunoglobulin chain.
- 15 7. Monoclonal antibody which binds to human IgE on the surface of B cells but does not bind to human IgE on the surface of basophils and does not bind to secreted, soluble IgE.
8. The monoclonal antibody of claim 7 which is a human antibody or an antibody fragment.
- 20 9. A chimeric antibody which binds specifically to human IgE on the

surface of B-cells, but does not bind to IgE on the surface of basophils and does not bind to secreted, soluble IgE, the antibody having a murine antigen binding region and a human heavy chain constant region.

- 5 10. A continuous, stable cell line which produces a monoclonal antibody which binds to human IgE on the surface of B-cells but does not bind to human IgE on the surface of basophils and does not bind to secreted, soluble IgE.
11. A cell line of Claim 10, which is a hybridoma.
- 10 12. Isolated DNA comprising functionally rearranged genes encoding the variable region of a light or heavy chain of an antibody which binds to IgE-bearing B cells but not to basophils or to secreted, soluble IgE.
13. A DNA construct comprising the DNA of Claim 12 linked to DNA encoding a human light or heavy chain constant region.
- 15 14. A myeloma cell transfected with the DNA construct of Claim 13, which secretes a chimeric antibody.
15. Monoclonal anti-idiotypic antibody specific for the paratope of an antibody which binds to IgE-bearing B cells but does not bind to basophils or to the secreted, soluble form of IgE.
- 20 16. An paratope-specific, anti-idiotypic antibody of Claim 15, which is a chimeric antibody having an antigen binding region of murine origin and a constant region of human origin.

17. An antigen binding fragment of the anti-idiotypic antibody of Claim 16.
18. An immunotoxin comprising a cytotoxin linked to an antibody which binds to IgE-producing B cells but does not bind to basophils or to secreted, soluble IgE.
- 5 19. An immunotoxin of Claim 18, wherein the cytotoxin is selected from the group consisting of cytotoxic steroids, gelonin, abrin, ricin, Pseudomonas toxin, diphtheria toxin, pokeweed antiviral peptide, tricarhecum, radioactive nuclides, and membrane lytic enzymes.
- 10 20. A bi-specific molecule comprising a first specific binding agent which binds to IgE-producing B lymphocytes but does not bind to mast cells or basophils or to secreted, soluble IgE and a second specific binding agent which binds to a receptor of a cytotoxic cell.
21. A bi-specific molecule of Claim 20, which is a bi-specific antibody.
22. A peptide having an amino acid sequence corresponding to the
15 extracellular segment of the membrane-bound domain of IgE on the surface of B cells.
23. A peptide of Claim 22, having the amino acid sequence:
Glu·Leu·Asp·Val·Cys·Val·Glu·Glu·Ala·Glu·Gly·Glu·Ala·Pro·Trp
and modifications of the peptide which do not substantially alter the
20 immunological properties thereof.
24. A monoclonal antibody or an antibody fragment reactive with the peptide of claim 23.

25. An ϵ immunoglobulin membrane anchoring peptide resulting from a mRNA splicing other than the splicing of the C ϵ 4 exon, the ϵ m1 exon, and the ϵ m2 exon.
26. A nucleotide fragment coding for the peptide of claim 25.
- 5 27. A peptide segment having the sequence:
GLAGG·SAQSQ·RAPDR·VLCHS·GQQQG·LPRAA·GGSVP·
HPRCH·CGAGR·ADWPG·PP and modifications of the peptide
which do not substantially alter the immunological properties thereof.
28. A peptide segment having the sequence:
10 GAAVP·LSHAA·GEAPD·LPRLH·QRPPA·PRLGR·
GHSRS·TRPSF·FSASA and modifications of the peptide which do
not substantially alter the immunological properties thereof.
29. A nucleotide fragment coding for the peptide segments of claim 27 or
28.
- 15 30. A DNA fragment including the sequence:
GGCTGGCTGG·CGGCTCCGCG·CAGTCCCAGA·
GGGCCCCGGA·TAGGGTGCTC·TGCCACTCCG·GACAGCA
GCA·GGGACTGCCG·AGAGCAGCAG·GAGGCTCTGT·CCC
CCACCCC·CGCTGCCACT·GTGGAGCCGG·GAGGGCTGAC·
20 TGGCCAGGTC·CCCCAG and corresponding sequences which code
for the same peptide.
31. A DNA fragment including the sequence:

GTGCAGGGT·TCCTCTCAGC·CAGCGGCAG·
GGGAGGCCCA·GACCTCCCT·CGACTACACC·AACGTCCT
CC·AGCCCCACGC·CTAGGCCGCG·GGCACTCACG·CTCCA
CCAGG·CCCAGCTTTT·TCTCTGCCAG·CGCCTGA and

5 corresponding sequences which code for the same peptide.

32. Monoclonal antibodies to the peptides of claim 27 or 28.

33. The monoclonal antibody of claim 32 which is human or chimeric
murine/human or an antibody fragment.

35. An anti-idiotypic antibody to the antibodies of claim 32.




Fig. 2A

CH4 domain | *me.1* exon
Isoform I --GTA·AAT·CCC·G AG·CTG·GAC·
V N P E L D

GTG·TGC·GTG·GAG·GAG·GCC·GAG·GGC·GAG·GCG·CCG·TGG.
V C V E E A E G E A P W

ACG·TGG·ACC·GGC·CTC·TGC·ATC·TTC·GCC·GCA·CTC·TTC·
T W T G L C I F A A L F

CTG·CTC·AGC·GTG·AGC·TAC·AGC·GCC·GCC·CTC·ACG·CTC·
L L S V S Y S A A L T L

| *me.2* exon
CTC·ATG·GTG·CAG·CGG·TTC·CTC·TCA·GCC·ACG·CGG·CAG·
L M V Q R F L S A T R Q

GGG·AGG·CCC·CAG·ACC·TCC·CTC·GAC·TAC·ACC·AAC·GTC·
G R P Q T S L D Y T N V

CTC·CAG·CCC·CAC·GCC·TAG·
L Q P H A *

Fig. 2B

Isoform II

CH4 domain | *me.p* segment
 ..GTA·AAT·CCC·G GG·CTG·GCT·
 V N P G L A

GGC·GGC·TCC·GCG·CAG·TCC·CAG·AGG·GCC·CCG·GAT·AGG·
 G G S A Q S Q R A P D R

GTG·CTC·TGC·CAC·TCC·GGA·CAG·CAG·CAG·GGA·CTG·CCG·
 V L C H S G Q Q Q G L P

AGA·GCA·GCA·GGA·GGC·TCT·GTC·CCC·CAC·CCC·CGC·TGC·
 R A A G G S V P H P R C

CAC·TGT·GGA·GCC·GGG·AGG·GCT·GAC·TGG·CCA·GGT·CCC·
 H C G A G R A D W P G P

CCA·G··*me.1* segment··*me.2* exon
 P

Fig. 2C

CH4 domain | me.2' exon
Isoform III ...GTA·AAT·CCC·G GT·GCA·GCG·
V N P G A A

GTT·CCT·CTC·AGC·CAC·GCG·GCA·GGG·GAG·GCC·CCA·GAC·
V P L S H A A G E A P D

CTC·CCT·CGA·CTA·CAC·CAA·CGT·CCT·CCA·GCC·CCA·CGC·
L P R L H Q R P P A P R

CTA·GCC·GCG·GGC·CAC·TCA·CGC·TCC·ACC·AGG·CCC·AGC·
L A A G H S R S T R P S

TTT·TTC·TCT·GCC·AGC·GCC·TGA·
F F S A S A *

Fig. 3A





Fig. 3B






Fig. 4

7/9

FIG. 5A




FIG. 5B




FIG. 5C






Fig. 6A



B

Fig. 6B



q/q




Fig. 7

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/00491

| | | |
|--|---|--------------------------|
| I. CLASSIFICATION OF SUBJECT MATTER (In several applications symbols apply, indicate all) * | | |
| According to International Patent Classification (IPC) or to both National Classification and IPC | | |
| IPC(5): C07K 7/00; 15/28; C12N 5/20, 5/12; A61K 39/395; C07H 15/00 | | |
| U.S. CL.: 530/350, 387, 389; 435/240.27, 240.2; 424/85.91; 536/27 | | |
| II. FIELDS SEARCHED | | |
| Minimum Documentation Searched * | | |
| Classification System | Classification Symbols | |
| U.S. | 530/350, 387, 389; 435/240.27, 240.2; 424/85.91; 536/27 | |
| Documentation Searched other than Minimum Documentation to the extent that such documents are included in the fields searched * | | |
| III. DOCUMENTS CONSIDERED TO BE RELEVANT * | | |
| Category * | Citation of Document, ** with indication, where appropriate, of the relevant passages ** | Relevant to Claim No. ** |
| Y | Nature. Vol. 307, issued 02 February 1984, Blattner et al. "The Molecular Biology of Immunoglobulin D", pages 417-422, see especially page 418, | 1-7, 9-24 |
| Y | Science. Vol. 229, ISSUED 30 SEPTEMBER 1987, Morrison, "Transfectomas Provide Novel Chimeric Antibodies", pages 1202-1207 see entire document. | 9, 13, 14, 16 |
| Y | WO.A. 89/05309 (KOHLER et al.) 15 JUNE 1989, see entire document. | 15-17 |
| Y | Science, vol. 229, issued 05 JULY 1985, Brennan et al "Preparation of Bispecific Antibodies by chemical Recombination of Monoclonal Immunoglobulin G. Fragments", pages 81-83, see entire document. | 20, 21 |
| Y | Cell, vol. 47, issued 05 December 1986, Pastan et al. "Immunotoxins", pages 641-648, See entire document. | 18-19 |
| <p>* Special categories of cited documents: **</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p> | | |
| IV. CERTIFICATION | | |
| Date of the Actual Completion of the International Search | Date of Mailing of this International Search Report | |
| 29 April 1991 | 10 JUN 1991 | |
| International Searching Authority | Signature: Authorized Officer | |
| ISA/US | Paula Hutzell | |

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE :

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers _____, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 8.4(e).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING :

This international Searching Authority found multiple inventions in this international application as follows:

See Attachment

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. **telephone practice**
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Attachment to form PCT/ISA/210; Box VI:

I. Claims 1-11, 15-19 and 24 drawn to monoclonal antibodies, hybridomas, chimeric antibodies, anti-idiotypic antibodies, chimeric anti-idiotypic antibodies and immunotoxins. Classes 530, 435 and 424 subclasses (387 and 389), 240.27 and 85.91.

II. Claims 12-14 drawn to isolated DNA constructs and a transfected myeloma. Classes 536 and 435, subclasses 27 and 240.2, respectively.

III. Claims 20 and 21 drawn to a biospecific molecule and bispecific antibody. Class 530, subclass 387.

IV. Claims 25-27, 29/27, 30, 32/37 and 35 drawn to peptides, nucleotide and DNA fragments, and monoclonal, chimeric and anti-idiotypic antibodies. Classes 536 and 530, subclasses 27 and (300 and 387) respectively.

V. Claims 22, 23 drawn to peptides. Class 530, subclass 300.

VI. Claims 28, 29/28, 31, 32/28, 33/28 and 35 drawn to a peptide, nucleotide and DNA fragments monoclonal, chimeric and anti-idiotypic antibodies. Classes 530 and 536, subclasses (387 and 300) and 27, respectively. Group I is directed to a first set of separate and distinct products. Group II is directed to a second set of separate and distinct products. Group III is directed to a third separate and distinct product. Group IV is directed to a fourth separate and distinct product. Group V is drawn to a fifth set of separate and distinct products. Group VI

is drawn to a sixth set of separate and distinct products. PCT
Rules 13.1 and 13.2 do not provide for multiple distinct products
within a single general inventive concept. ...